Drug Discovery Medicine

Narumiya, Shuh, M.D., Ph.D. Professor btn

At the Department of Drug Discovery Medicine, we work closely with supporting pharmaceutical companies and nurture people with talents required for drug discovery and development in a new era. We accept both medical graduates and graduates from other disciplines for our master’s and doctoral program. The goal of our curriculum is to make graduates ready to work in a wide variety of positions in drug discovery and development, including (not limited) researchers both in academia and pharmaceutical companies, entrepreneurs, managers in drug discovery and development, and managers in academia-pharma collaboration.

Research and Education

In Layer 1 of our program, lectures and laboratory courses will be provided for non-MD students to acquire systematic knowledge of core basic science in medicine. In Layer 2, all students further acquire essential knowledge in the current drug discovery and development such as clinical human genetics, bioinformatics, etc. and, in Layer 3, they participate in a series of seminars studying pathophysiology of human diseases and engaging in active discussion on target identification and development of new therapeutic modalities using several diseases as representative examples. Finally, in Layer 4, trainees are exposed to studies in wider areas related to drug discovery and development such as bio-bank, big data science, precision medicine, clinical trials, intellectual properties, regulatory science, and business models, all of which are important in filling gaps among academia, companies and society to facilitate delivery of drugs to the patients. In parallel with such educational course works, students conduct their own research projects by participating in academia-pharma collaborative projects ongoing at the Medical Innovation Center and other departments of Kyoto University.

Recent Publications

  1. Narumiya, S., Thumkeo, D, (2018) Rho Signaling Research: History, Current Status and Future Directions. FEBS Lett., in press
  2. Aoki, T. et al. (2017) Prostaglandin E2-EP2-NF-κB signaling in macrophages as a potential therapeutic target for intracranial aneurysms. Science Signaling, 10(465). pii: eaah6037.
  3. Deguchi, Y. et al.(2016) mDia and ROCK Mediate Actin-Dependent Presynaptic Remodeling Regulating Synaptic Efficacy and Anxiety. Cell Reports, 17, 2405-2417.
  4. Takeshi Sakurai et al. (2011) Haploinsufficiency of Gtf2i, a gene deleted in Williams syndrome, leads to increase in social interactions. Autism Research, 4, 28-39.
  5. Takeshi Sakurai et al. (2015) Converging models of schizophrenia – Network alterations of prefrontal cortex underlying cognitive impairments – Progress in Neurobiology, 134, 178-201.

Drug Discovery Medicine

Professor and Chair: Narumiya, Shuh
Professor: Tsuruyama, Tatsuaki
Professor: Sakurai, Takeshi
Professor: Saotome, Chikako
Associate Professor: Fujimoto, Akihiro
Associate Professor: Thumkeo, Dean
Senior Lecturer: Hiratsuka, Takuya
Assistant Professor: Ajiro, Masahiko